PPARγ Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study
Activating synthetic ligands for peroxisome proliferator-activated receptor gamma (PPARγ), such as pioglitazone, are commonly used to treat persons with diabetes mellitus with improvement of insulin resistance. Several reports have clearly demonstrated that PPARγ ligands could inhibit colorectal can...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Wiley
2010-01-01
|
| سلاسل: | PPAR Research |
| الوصول للمادة أونلاين: | http://dx.doi.org/10.1155/2010/257835 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|